CD2
T-cell surface antigen CD2
As of the edition of 20 October 2026, CD2 (T-cell surface antigen CD2, UniProt P06729) has 2 drugs tested at it and 5 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P06729
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Skin and connective tissue; Immune system; Blood and lymph; Cancer; Inherited and neonatal; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 58
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Alefacept | Marketed | Phase 4 | Ended 2015 |
| Siplizumab | Active | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Engaged | 1 |
| Undetermined | 2 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| ITB-Med | Route A |
The other 3 companies at CD2
In the product5 companies in all; 3 are not named here, and no score is.
See the 5 companies at CD2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.